Long-standing scarcity of efficacious treatments and tumor heterogeneity have contributed to
triple-negative breast cancer (TNBC), a subtype with a poor prognosis and aggressive …

Triple-negative breast cancer (TNBC) accounts for 15–20% of all invasive breast cancer
subtypes. Owing to its clinical characteristics, such as the lack of effective therapeutic …

Triple negative breast cancer (TNBC) displays a high aggressive behavior, tendency to
relapse and early metastasize, leading to poor prognosis. The lack of estrogen receptors …

Hypothesis Tumor-associated macrophages (TAM) are the mainstay of immunosuppressive
cells in the tumor microenvironment, and elimination of M2-type macrophages (M2-TAM) is …

Insufficient accumulation of drug at the tumor site and the low drug response are the main
reason for the unsatisfactory effect of cancer therapy. Delivery drugs exquisitely to …

Currently, the treatment of triple-negative breast cancer (TNBC) is limited by the special
pathological characteristics of this disease. In recent years, photodynamic therapy (PDT) has …

Introduction Triple negative breast cancer (TNBC) is a rare but aggressive biological
subtype of breast cancer associated with higher locoregional and distant recurrence rates …

Simple Summary Breast cancer is a global burden with the most severe subtype being triple
negative breast cancer (TNBC). Despite advances in conventional therapies, treatment for …

Objective To explore the role of p300 in the context of paclitaxel (PTX) resistance in triple-
negative breast cancer (TNBC) cells, focusing on its interaction with the …

Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer
characterized by an unfavorable prognosis due to its aggressive biology. Cancer-associated …